

PLANNED BOARD CHANGES

INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) advises that Chairman David Williams has announced his intention to step down as Chairman at year-end or upon the announced appointment of a new Chair.

Mr William's decision was driven by the completion of the recent capital raising, the securing of a new Chinese cornerstone investor and addition of Peter Gunzburg (previously Chairman of BARD1 Life Sciences Limited, now INOVIQ Ltd, from 2016 to 2020) to the Board allowing David to focus on other business interests.

Under David's leadership, INOVIQ has achieved key strategic milestones, transitioning core programs from research to development, advancing its EXO-OC ovarian cancer test, progressing its CAR-Exosome therapeutic program, and expanding commercialisation of its EXO-NET exosome capture technology across multiple platforms. The Company has also bolstered its leadership team with new senior appointments and is well-positioned to deliver on its strategic objectives over the next 12 months.

Commenting on his decision, Mr Williams said: *"The role I came on board to fulfil is now advanced. INOVIQ has made excellent progress across its diagnostic and therapeutic programs, having moved them from research into development and commercialisation. The company is in a strong position for success."*

INOVIQ Director Max Johnston added: *"David's strategic insight and commercial acumen combined with his energy have been invaluable in shaping INOVIQ's asset portfolio and growth strategy. On behalf of the Board and management team, we thank David for his leadership and significant contribution to shaping INOVIQ's future."*

Authorised for release by Company Secretary, Mark Edwards.

FURTHER INFORMATION

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

David Williams
Chairman
E dwilliams@kidder.com.au
M +61 414 383 593

Max Johnston
Non-Executive Director
M +61 412 041 298

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology advancing next-generation diagnostics and therapeutics to transform cancer care. Our product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a cutting-edge preclinical CAR-exosome therapeutic program for solid tumours. INOVIQ is shaping the future of cancer detection and treatment to improve patient outcomes. For more information on INOVIQ, visit www.inoviq.com.